---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-035203"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:52:32.544740+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC updates registrational plans for lead drugs, extends cash runway into 2027

## Summary
- ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.
- ORIC-114 registrational focus on 1L NSCLC with Phase 3 trials planned 2026; 2L/2L+ registration deprioritized.
- Comprehensive NSCLC data update expected 2H 2025 including 1L EGFR exon 20 and atypical cohorts.
- Cash, cash equivalents and investments totaled $256M as of Dec 31, 2024; projected runway extended into 2027.

## SEC filing metadata
- accession: 0001193125-25-035203
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312525035203/0001193125-25-035203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312525035203/d830999d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-035203
- JSON: https://secwatch.observer/filing/0001193125-25-035203.json
- Plain text: https://secwatch.observer/filing/0001193125-25-035203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.